Skip to content


BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy

  • Giuliano Ramadori1Email author,
  • Patrizia Bosio2,
  • Federico Moriconi3 and
  • Ihtzaz A. Malik4
BMC Cancer201818:257

Received: 4 September 2017

Accepted: 1 March 2018

Published: 6 March 2018



After orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC), recurrent HCC mostly develops within 2 years. All cases of de novo HCC described so far occurred later than 2 years after OLT. Prevention of post-transplantation HCC has usually been tried to achieve by curing or controlling recurrent liver disease. This has been rationale for treatment with interferon (IFN)/ribavirin of HCV-recurrence in patients after OLT, transplanted for advanced HCV-induced liver disease and/or HCC. The availability of new and more efficient drugs has improved chances also for previously difficult-to-treat HCV-positive patients.

Case presentation

A 75 year-old male patient who had undergone OLT for decompensated HCV-cirrhosis in 2009, and bilio-digestive surgery in 2011 under tracrolimus (0.5 mg/day) and prednisone (5 mg/day) immunosuppressive therapy, started to receive antiviral treatment for recurrent HCV-infection of graft with 200 mg/day ribavirin in combination with ledipasvir and sofosbuvir by the end of October 2015. Because of multiple side effects (anemia, asthenia, infections, and reduction of kidney functions - palliated by treatment with erythropoietin), treatment was stopped after 16 weeks. At the third control, a minimal increase in alpha-fetoprotein (AFP) serum level to 10 μg/L was measured 8 months after therapy, whereas both liver sonography and serum transaminases were normal. The patient’s general condition; however, remained poor, and a magnetic resonance imaging (MRI) of abdomen was performed 2 months later. A nodule of 3 cm in diameter with a pseudocapsule was found centrally in the liver. The patient had to be hospitalized for recurrent infections of the lung, overt ascites and peritonitis. Rapid tumor growth (10 cm) was detected during last stay in hospital (April 2017), concomitant with a rise of AFP-serum levels to 91 μg/L. The family decided to take the patient home, and best supportive care was provided by a general practitioner, local nurses and the patient’s dedicated wife until his death.


Before treating OLT patients with HCV graft reinfection one should not only consider possible advantages of newly effective antiviral-therapies, but also life expectancy and possible side effects (difficult to manage at an outpatient service basis), including severe disadvantages such as the development of HCC.


Hepatocellular carcinomaLiver transplantationHepatitis C virusInterferonRibavirin


Worldwide, approximately 180 million people are infected with the hepatitis C virus (HCV) [1]. Twenty to 30% of the infected people will develop liver cirrhosis, and among these, appr. 5% are in danger to develop liver cancer [2]. In the IFN era, about 50% of the patients infected with HCV genotype 1 (G1) achieved sustained virological response (SVR) [3]. HCV-infection is considered to be a major cause of liver cancer development [4], and infections may still develop in cirrhotic patients even after HCV-eradication [5]. Recently, an interesting French nationwide report pointed out that only 8% of the reported liver tumor cases were specifically due to HCV-infection [6]. This could be an explanation for the fact that, statistically, HCV-eradication may not guarantee longer life expectancy compared to persons not having received HCV-eradication [7]. HCV-induced liver cirrhosis and liver cancer are the key indicators for liver transplantation [8]. Chronic hepatitis and cirrhosis may quickly develop after reinfection of the graft in HCV-patients receiving orthotopic liver transplantation (OLT) for HCV-positive advanced liver cirrhosis or hepatocellular carcinoma (HCC) [9, 10]. In transplant centers, HCV-eradication therapy has been performed before and/or after transplantation, and successful viral elimination has been reported under combination of Peg-IFN and ribavirin, administered for different periods [11, 12]. Sustained virological response after both OLT and kidney transplantation has been shown to improve the overall survival in patients with HCV-infection [1318].

Nowadays, anti HCV-therapies have been successively replaced by IFN-free direct-acting-antiviral (DAA) agents with or without ribavirin, leading to a reduction of therapy duration (12–24 weeks), and to an improvement of viral elimination rates to almost 100% for all difficulty grades and viral genotypes [19, 20]. In 2015, the combination of ladispovir / sofusbovir and ribavirin for 24 weeks in patients with HCV-reinfection after OLT was considered gold-standard, with therapy beginning at any time after transplantation [20].

Recurrence of HCC has been observed in a number of cases, even after successful elimination of HCV before or after OLT [2124]. De novo HCC-development after OLT, however, is a very rare event, and only a few cases have been described so far [25]. A few reports demonstrated an increase of HCC development or recurrence in patients with liver cirrhosis due to HCV-infection and SVR after IFN-free treatment [26, 27] outside the transplantation setting. In contrast, de novo HCC development after having achieved SVR in patients transplanted for HCV-cirrhosis has not yet been described [25].

Case presentation

In July 2009, a 69-year-old male patient with decompensated HCV-cirrhosis underwent OLT. Postoperative time was complicated by bile duct anastomosis leakage, which was then treated with surgical bilio-digestive anastomosis in 2011. In 2012, liver histology showed bridging fibrosis, but no clear signs of cirrhosis. During the following years, a mild subclinical cholestasis was treated with oral deoxycholic acid. Immunosuppression was performed with tacrolimus (0.5 mg/day) and prednisone (5 mg/day). Despite viral reinfection and repeated episodes of cholangitis with pruritus, successfully treated with antibiotics, graft function was preserved with acceptable quality of life. As electrography on the graft reached 25 kPa, therapy with ledipasvir (90 mg) / sofusbovir (400 mg) combined with a reduced dosage of ribavirin (200 mg) was started by the end of October 2015. While HCV-negativity was found after 4 weeks of therapy, severe asthenia, loss of appetite and repeated infections developed together with progressive anemia. The latter persisted in spite of weekly subcutaneous administration of erythropoietin. Subsequently, reduction of kidney glomerular filtration rate developed. For this reason, therapy was stopped after 16 weeks while the patient developed ascites and edema of the legs in spite of improvement of liver stiffness down to 15 kPa. After two episodes of pneumonia and repeated laboratory and sonography surveillance (performed by experienced radiologists), 8 months after the end of treatment a first mild increase of serum AFP was detected, while ultrasonography (Fig. 1) did not detect any nodules in the liver. Two months later, a nodule of 3 cm size was detected by multiphasic-MRI (performed with administration of Gd-BOPTA) in the center of the left hepatic lobe (segment 2 (S2)), and a second smaller (1.5 cm) nodule in S4. The hyperintensity of the main lesion on T1-weighted images with enhancement in the arterial phase and with delayed portal venous wash-out [28] was judged to be suspicious for HCC according to the guidelines of the European Society for Medical Oncology (ESMO) (Figs. 2, 3 and 4). The multitude of the lesions led to the decision of therapeutic non-intervention, and best supportive care was offered to the patient in a tertiary care hospital.
Fig. 1

Liver ultrasound examination performed 10 months after the end of treatment when AFP was 10 ng/ml. No signs of liver cirrhosis and no signs of tumor were detectable

Fig. 2

MRI-investigation of the liver 12 months after end of treatment with SVR; a nodule (3 cm diameter) with the characteristic of a HCC was detected in the left liver lobe (arrow), while a further small nodule was suspected (smaller arrow). No signs of cirrhosis were detectable

Fig. 3

Additional slice of the MRI showing the nodule in S2 (arrow) 12 months after the end of treatment and SVR

Fig. 4

MRI investigation of the liver as described in Fig. 2. A third nodule (1.2 cm diameter) was described in the right liver lobe (arrow)

General physical conditions continuously worsened. An MRI of the liver performed by the end of April 2017 (Figs. 5 and 6) showed a massive increase in size of the former central nodule to 10 cm, completely occupying the left liver lobe, accompanied by an increase of serum AFP levels to 91 ng/ ml (Table 1). The family decided to take the patient home where he was having palliative care from his dedicated wife, from his home doctor and nurse.
Fig. 5

MRI-investigation 16 months after end of treatment. A rapid growth of the nodule in the left liver lobe was appreciable

Fig. 6

MRI of the liver as described in Fig. 2; the size of the subcapsular nodule (smaller arrow) has not increased compared to that of Fig. 1. The supposed third nodule (Fig. 4) was not confirmed

Table 1

Characteristics of the patient with de novo tumor in the liver graft


























































































Fibro/Scan (kPa)






aAlbumin (20%) infusions were given depending on availability


HCV-infection alone or in combination with other damaging noxae such as alcoholic beverages or xenobiotics can lead to chronic hepatitis, cirrhosis and liver cancer (HCC). Risk of tumor development has been shown to be significantly reduced in patients who achieved sustained virological response (SVR) after antiviral therapy consisting of IFN-alpha and ribavirin. Long-term follow-up studies will reveal whether this is the case also for the highly effective new IFN-free therapies with directly-acting-antiviral (DAA) drugs with or without ribavirin [5, 2932].

Decompensated liver cirrhosis and liver cancer still remain the principal indications for liver transplantation. Recurrence of HCV-infection in the graft, however, is a common adverse event immediately after liver transplantation. Reinfection and the concomitant administration of various drugs leads to the development of liver cirrhosis in about 20 to 30% of the transplanted patients within 5 years after transplantation, with reduction of overall survival compared to alcoholic liver disease [10]. The introduction of new drugs has ignited the discussion about the timing when therapy should be administered, namely before or after transplantation, and, if after transplantation, at which time point exactly?

Some reports have initiated a debate about the possibility of an increased frequency of liver cancer, which may be seen within months after the end of treatment in patients with SVR, who were previously operated for HCC-resection [26]. An increased incidence of HCC has also been reported in patients with liver cirrhosis after SVR achieved with IFN-free therapy [27]. This danger seems to be higher in older patients with more advanced cirrhosis [3342]. Recurrence of liver tumor after OLT for HCC (mostly outside the liver) is a well-known complication, and the advantages of antiviral therapy during the patient’s stay on the waiting list [26, 43] or after OLT has not yet been proven.

Although we cannot exclude the possibility of the presence of tumor cells in liver at the beginning of DAA-therapy, this is the first case report on de novo liver cancer shortly after DAA-induced HCV-elimination in a patient who received long-term treatment after OLT. It is not yet clear how anti-viral treatment could be responsible for tumor development and/or acceleration of tumor growth. One possibility is that prolonged immunosuppression may be aggravated by antiviral agents (including ribavirin), thereby supporting the growth of scattered tumor cells, which have escaped immunosurveillance and were already present at the start of antiviral therapy.

Development of de novo HCC in patients transplanted for advanced liver cirrhosis without clinical signs of cancer is a very rare event. In fact, it has been thought that successful antiviral therapy and alcohol abstinence should prevent cirrhosis and carcinogenesis in the graft, and patients may rather die for other medical complications before the occurrence of cirrhosis and cancer.

Indeed, the early appearance of HCC in the graft after transplantation may represent the recurrence of a pre-existing tumor in the explanted liver, which was not detectable at the time of transplantation. This can only be proven through molecular analyses of the tumor material, which would allow the identification of donor or recipient origin. De novo HCC has also been reported in patients with HCV-reinfection, who achieved SVR after antiviral therapy with IFN and ribavirin [44]. Recurrence of cirrhosis has been confirmed to be a risk factor for de novo HCC-development in the re-infected graft, as is true for patients with HCV-positive liver diseases before transplantation. In one reported case, a tumor developed in a 59-year-old female patient transplanted for HCV-positive HCC, 6 years after living-donor liver transplantation and 2 years after signs of decompensated liver cirrhosis. She was successfully treated with antiviral therapy (Peg-IFN and ribavirin) for 48 weeks [44]. A CT-scan of the liver detected a hepatic nodule of 1 cm size, which was radiologically diagnosed as a classical HCC. The patient had higher AFP-serum levels during 6 months after CT-scan. Liver function tests were, however, within the normal range. Tumor resection was performed, and a tumor of 0.9 cm in size with trabecular growth and desmoplastic changes was diagnosed histologically. The non-tumorous liver tissue was cirrhotic with inflammatory infiltrates of the fibrotic septa. Genotyping of DNA samples extracted from the tumorous and non-tumorous tissue from the graft and the donor indicated that it was a de novo HCC, diagnosed 2 years after end of treatment, and about 2.5 years after confirmation of negative serum HCV-RNA level under antiviral treatment. Our patient developed detectable tumors and a minor increase in serum-AFP level 12 months after start of DAA-therapy and 8 months after the end of therapy. HCC was diagnosed based on the MRI-finding of liver tumor(s), and elevated AFP-serum level. However, in consideration of the reduced physical conditions and of the rather decreasing liver function parameters, in spite of normal transaminase serum levels, no further local or systemic anti-tumoral therapeutic measures were taken into consideration while a rapid and massive growth of the main tumor was detectable 4 months later.

At this time, patient had to be hospitalized for ascites edema of the legs, attacks of abdominal pain and fever. Recurrent bacterial peritonitis was treated with antibiotics. When diagnosis of a growing tumor was confirmed by MRI, he was sent home for best supportive care by his dedicated wife, home doctor and nurse until his death (June 12th, 2017).


Decision of treating patients suffering of HCV-infection after liver transplantation with DAA-drugs should take in consideration possible side effects including cancer development and life expectancy.





Direct-acting antiviral




Genotype 1


Hepatocellular carcinoma


Hepatitis C virus




Magnetic resonance imaging


Orthotopic liver transplantation


Sustained virological response



We thank the patient and his family for consent and participation.


Not applicable

Availability of data and materials

All data, which is generated and analyzed is included in this report.

Authors’ contributions

GR, PB and FM collected and analyzed the data: GR and IAM interpreted the data. All authors were involved in writing manuscript, and final version of the manuscript is read and approved by all authors.

Ethics approval and consent to participate

Not applicable

Consent for publication

Written informed consent was obtained from the patient and his guardians for participation in the study design, data collection and treatment as well as publication. The case report was prepared according to CARE guidelines.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Gastroenterology and Endocrinology, University Medical Center Goettingen, Goettingen, Germany
General Practitioner, National health care system, Palazzago, Italy
Gastro-Centro, Lugano, Switzerland
Institute of Anatomy and Cell Biology, University Medical Center, Goettingen, Germany


  1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42.View ArticlePubMedGoogle Scholar
  2. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61:S58–68.View ArticlePubMedGoogle Scholar
  3. Amanzada A, Schneider S, Moriconi F, Lindhorst A, Suermann T, van Thiel DH, et al. Early anemia and rapid virological response improve the predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination therapy in patients infected with chronic HCV genotype 1. J Med Virol. 2012;84:1208–16.View ArticlePubMedGoogle Scholar
  4. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329–37.View ArticlePubMedGoogle Scholar
  5. Li DK, Chung RT. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis. Cancer. 2015;121:2874–82.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Goutté N, Sogni P, Bendersky N, Barbare JC, Falissard B, Farges O. Geographical variations in incidence, management and survival of hepatocellular carcinoma in a western country. J Hepatol. 2017;66:537–44.View ArticlePubMedGoogle Scholar
  7. Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. J Hepatol. 2017;66:19–27.View ArticlePubMedGoogle Scholar
  8. Roche B, Samuel D. Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: a costly strategy for mixed virological results. J Hepatol. 2009;50:652–4.View ArticlePubMedGoogle Scholar
  9. Féray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European concerted action on viral hepatitis (EUROHEP) group. Gastroenterology. 1999;117:619–25.View ArticlePubMedGoogle Scholar
  10. Forns X, García-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003;39:389–96.View ArticlePubMedGoogle Scholar
  11. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42:255–62.View ArticlePubMedGoogle Scholar
  12. Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142:1373–1383.e1.View ArticlePubMedGoogle Scholar
  13. Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown RS, Saab S, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013;57:1752–62.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Aleman S, Rahbin N, Weiland O, Davidsdottir L, Hedenstierna M, Rose N, et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis. 2013;57:230–6.View ArticlePubMedGoogle Scholar
  15. Jiménez-Pérez M, González-Grande R, Rando-Muñoz FJ. Management of recurrent hepatitis C virus after liver transplantation. World J Gastroenterol. 2014;20:16409–17.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol. 2013;58:1028–41.View ArticlePubMedGoogle Scholar
  17. Dumitra S, Alabbad SI, Barkun JS, Dumitra TC, Coutsinos D, Metrakos PP, et al. Hepatitis C infection and hepatocellular carcinoma in liver transplantation: a 20-year experience. HPB. 2013;15:724–31.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Sanai FM, Mousa D, Al-Mdani A, Al-Shoail G, Al-Ashgar H, Al Meshari K, et al. Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C. J Hepatol. 2013;58:1096–103.View ArticlePubMedGoogle Scholar
  19. Fagiuoli S, Ravasio R, Lucà MG, Baldan A, Pecere S, Vitale A, et al. Management of hepatitis C infection before and after liver transplantation. World J Gastroenterol. 2015;21:4447–56.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Coilly A, Roche B, Duclos-Vallée J-C, Samuel D. Optimum timing of treatment for hepatitis C infection relative to liver transplantation. Lancet Gastroenterol Hepatol. 2016;1:165–72.View ArticlePubMedGoogle Scholar
  21. Singal AK, Freeman DH, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010;32:851–8.View ArticlePubMedGoogle Scholar
  22. Xu J, Li J, Chen J, Liu Z-J. Effect of adjuvant interferon therapy on hepatitis b/c virus-related hepatocellular carcinoma after curative therapy - meta-analysis. Adv Clin Exp Med Off Organ Wroclaw Med Univ. 2015;24:331–40.View ArticleGoogle Scholar
  23. Hsu Y-C, Ho HJ, Wu M-S, Lin J-T, Wu C-Y. Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatology. 2013;58:150–7.View ArticlePubMedGoogle Scholar
  24. Zhang D-W, Song T-Q, Zhang T, Wu Q, Kong D-L, Li Q, et al. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: a meta-analysis with comparison of different types of hepatitis. Mol Clin Oncol. 2014;2:1125–34.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Trevisani F, Garuti F, Cucchetti A, Lenzi B, Bernardi M. De novo hepatocellular carcinoma of liver allograft: a neglected issue. Cancer Lett. 2015;357:47–54.View ArticlePubMedGoogle Scholar
  26. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, Lens S, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65:719–26.View ArticlePubMedGoogle Scholar
  27. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65:727–33.View ArticlePubMedGoogle Scholar
  28. Lencioni R, Cioni D, Crocetti L, Della Pina C, Bartolozzi C. Magnetic resonance imaging of liver tumors. J Hepatol. 2004;40:162–71.View ArticlePubMedGoogle Scholar
  29. Hézode C, Bronowicki J-P. Ideal oral combinations to eradicate HCV: the role of ribavirin. J Hepatol. 2016;64:215–25.View ArticlePubMedGoogle Scholar
  30. Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol. 2016;27:1467–74.View ArticlePubMedGoogle Scholar
  31. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493–505.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152:142–156.e2.View ArticlePubMedGoogle Scholar
  33. Nault J-C, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: controversy after the revolution. J Hepatol. 2016;65:663–5.View ArticlePubMedGoogle Scholar
  34. Toyoda H, Kumada T, Tada T. Changes in patient backgrounds may increase the incidence of HCC after SVR in the era of IFN-free therapy for HCV. Hepatology. 2016;64:1818–9.View ArticlePubMedGoogle Scholar
  35. Ravi S, Axley P, Jones D, Kodali S, Simpson H, McGuire BM, et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology. 2017;152:911–2.View ArticlePubMedGoogle Scholar
  36. Tsai P-C, Huang C-F, Yu M-L. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: issue of the interval between HCC treatment and antiviral therapy. J Hepatol. 2017;66:464.View ArticlePubMedGoogle Scholar
  37. Kolly P, Dufour J-F. A strong message is needed to address the issue of HCC recurrence after DAA therapy. J Hepatol. 2016;65:1268–9.View ArticlePubMedGoogle Scholar
  38. Carrat F, Nahon P, Duclos-Vallée JC, Pageaux GP, Fontaine H, Pol S, et al. Reply to “a strong message is needed to address the issue of HCC recurrence after DAA therapy”. J Hepatol. 2016;65:1269–70.View ArticlePubMedGoogle Scholar
  39. Zavaglia C, Okolicsanyi S, Cesarini L, Mazzarelli C, Pontecorvi V, Ciaccio A, et al. Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured? J Hepatol. 2017;66:236–7.View ArticlePubMedGoogle Scholar
  40. Zeng Q-L, Li Z-Q, Liang H-X, Xu G-H, Li C-X, Zhang D-W, et al. Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: too alarming? J Hepatol. 2016;65:1068–9.View ArticlePubMedGoogle Scholar
  41. Torres HA, Vauthey J-N, Economides MP, Mahale P, Kaseb A. Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: first, do no harm by withdrawing treatment. J Hepatol. 2016;65:862–4.View ArticlePubMedGoogle Scholar
  42. Reig M, Torres F, Mariño Z, Forns X, Bruix J. Reply to “direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: much ado about nothing”. J Hepatol. 2016;65:864–5.View ArticlePubMedGoogle Scholar
  43. Yang JD, Aqel BA, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. J Hepatol. 2016;65:859–60.View ArticlePubMedGoogle Scholar
  44. Morita K, Taketomi A, Soejima Y, Ikegami T, Fukuhara T, Iguchi T, et al. De novo hepatocellular carcinoma in a liver graft with sustained hepatitis C virus clearance after living donor liver transplantation. Liver Transpl. 2009;15:1412–6.View ArticlePubMedGoogle Scholar


© The Author(s). 2018